Pacira BioSciences Quarterly Balance Sheet
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pacira BioSciences financial position
As of Jun 30, 2026, Pacira BioSciences reported total assets of $1.24 billion, down 19.1% from a year earlier against total liabilities of $572.0 million. Shareholders' equity stood at $672.0 million, or 54.0% of assets. The company held $205.9 million in cash and equivalents against $363.1 million of debt, a net debt position of $157.2 million.
The current ratio (current assets divided by current liabilities) was 5.04, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.54.
Summary generated from market data by MetaCap's automated system. Methodology
Pacira BioSciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 205.88M | 144.31M | 158.54M | 147.59M | 300.48M | 283.61M | 276.77M | 245.97M | 247.05M | 184.05M | 153.30M | 99.12M |
| Short-Term Investments | 45.16M | 57.87M | 79.88M | 98.75M | 145.38M | 210.02M | 207.84M | 207.84M | 157.17M | 141.84M | 125.28M | 136.07M |
| Receivables | 132.42M | 125.64M | 124.07M | 115.27M | 114.37M | 104.75M | 113.30M | 100.65M | 104.78M | 101.64M | 105.56M | 96.96M |
| Inventory | 134.57M | 150.37M | 152.86M | 157.68M | 148.16M | 133.75M | 125.28M | 111.86M | 103.44M | 96.78M | 104.35M | 96.52M |
| Total Current Assets | 615.22M | 514.96M | 547.97M | 562.75M | 745.61M | 759.96M | 745.13M | 689.97M | 632.21M | 543.11M | 509.99M | 447.25M |
| Property, Plant & Equipment | 130.28M | 136.28M | 140.69M | 147.39M | 155.18M | 164.45M | 167.17M | 166.85M | 168.85M | 171.80M | 173.93M | 175.78M |
| Goodwill | 19.64M | 19.77M | 20.21M | 20.32M | 20.30M | 21.52M | 0 | 0 | 163.24M | 163.24M | 163.24M | 163.24M |
| Intangible Assets | 285.48M | 353.23M | 368.10M | 382.40M | 422.56M | 434.97M | 425.97M | 440.29M | 454.61M | 468.94M | 483.26M | 497.58M |
| Long-Term Investments | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 2.41M | 0 |
| Total Assets | 1.24B | 1.21B | 1.26B | 1.30B | 1.54B | 1.59B | 1.55B | 1.52B | 1.65B | 1.58B | 1.57B | 1.53B |
| Accounts Payable | 17.51M | 14.01M | 15.15M | 17.69M | 30.12M | 23.17M | 19.13M | 19.37M | 18.73M | 8.98M | 15.70M | 16.51M |
| Short-Term Debt | — | — | 0 | 0 | — | — | 201.78M | — | — | — | — | — |
| Total Current Liabilities | 122.01M | 108.79M | 120.59M | 107.08M | 313.16M | 314.73M | 309.92M | 306.40M | 92.69M | 93.44M | 97.38M | 93.66M |
| Long-Term Debt | 363.12M | 367.66M | 372.19M | 376.72M | 580.49M | 583.38M | 383.55M | — | — | — | 522.44M | — |
| Total Liabilities | 572.00M | 554.64M | 571.81M | 570.36M | 779.50M | 788.13M | 775.17M | 772.11M | 767.54M | 691.16M | 704.26M | 702.91M |
| Shareholders' Equity | 671.98M | 653.89M | 693.11M | 727.21M | 757.77M | 798.54M | 778.35M | 749.58M | 879.28M | 892.16M | 870.13M | 831.55M |
| Retained Earnings | -191.75M | -196.41M | -199.32M | -200.96M | -206.39M | -201.54M | -206.36M | -222.40M | -78.93M | -97.82M | -106.80M | -131.67M |
| Total Debt | 363.12M | 367.66M | 372.19M | 376.72M | 580.49M | 583.38M | 585.32M | — | — | — | 522.44M | — |
| Net Cash (Debt) | -112.09M | -165.48M | -133.76M | -130.39M | -134.63M | -89.75M | -100.71M | 453.81M | 404.23M | 325.89M | -243.86M | 235.19M |
| Shares Outstanding | 39.82M | 39.31M | 41.12M | 42.97M | 44.90M | 46.28M | 46.24M | 46.15M | 46.12M | 46.52M | 46.48M | 46.43M |
This table shows 12 quarterly periods of Pacira BioSciences's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow PCRX's reporting calendar. What is a balance sheet?